NIH VideoCast - Developing Treatment for Hereditary Neuromuscular Disease

Skip Navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Developing Treatment for Hereditary Neuromuscular Disease

Loading... Loading video...

424 Views

Air date:	Wednesday, November 2, 2011, 3:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 424 (79 Live, 345 On-demand)
Category:	WALS - Wednesday Afternoon Lectures
Runtime:	01:10:01
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	Several thousand human disease genes have been identified over the past 25 years. The challenge now is to convert what we know about the causes and mechanisms of hereditary diseases into safe and effective treatment. We are finally close to doing this for two pediatric neuromuscular diseases, Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). DMD is characterized by progressive weakness due to muscle degeneration. The disease is caused by mutations in the muscle protein dystrophin. Most of the mutations are partial gene deletions that shift the translational reading frame of the mRNA, leading to a truncated and unstable protein. Approaches to treatment include enhancing muscle regeneration and replacing or correcting the gene at the DNA or mRNA level. Myostatin inhibition and drugs that promote read-through of mutations have shown benefit in animals but not yet in clinical trials. Gene replacement has low efficiency and may induce an immune response to dystrophin. Oligonucleotide therapy to induce exon skipping may be the most promising approach at present. The oligonucleotides target specific mutations at the mRNA level. Recent clinical studies have shown partial restoration of muscle dystrophin with local and systemic delivery, and international trials are in progress. SMA is the most common severe hereditary disease of infancy. It is characterized by weakness of the extremity and respiratory muscles due to motor neuron loss. SMA is caused by mutations that lead to reduced levels of the survival motor neuron (SMN) protein, which is an important factor in mRNA splicing. Motor neurons may be particularly vulnerable to SMN deficiency because of their unusual structure and function. A variety of cell and animal models are available to test potential SMA treatments. Histone deacetylase inhibitors are beneficial in mice, and this effect can be enhanced by improved nutrition. Clinical trials of drugs that increase SMN have had mixed results to date, and assays to screen for better drugs have been developed. Oligonucleotide and gene replacement therapy have recently shown great promise in animal studies, and clinical trials are planned. Meanwhile, there is evidence that better respiratory and nutritional support can be very helpful. Thus, the clinical outcome may be improved by optimizing currently available treatment. The NIH Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide. For more information, visit: The NIH Director's Wednesday Afternoon Lecture Series

NLM Title:	Developing treatment for hereditary neuromuscular disease / Kenneth Fischbeck.
Author:	Fischbeck, Kenneth. National Institutes of Health (U.S.)
Publisher:
Abstract:	(CIT): Several thousand human disease genes have been identified over the past 25 years. The challenge now is to convert what we know about the causes and mechanisms of hereditary diseases into safe and effective treatment. We are finally close to doing this for two pediatric neuromuscular diseases, Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). DMD is characterized by progressive weakness due to muscle degeneration. The disease is caused by mutations in the muscle protein dystrophin. Most of the mutations are partial gene deletions that shift the translational reading frame of the mRNA, leading to a truncated and unstable protein. Approaches to treatment include enhancing muscle regeneration and replacing or correcting the gene at the DNA or mRNA level. Myostatin inhibition and drugs that promote read-through of mutations have shown benefit in animals but not yet in clinical trials. Gene replacement has low efficiency and may induce an immune response to dystrophin. Oligonucleotide therapy to induce exon skipping may be the most promising approach at present. The oligonucleotides target specific mutations at the mRNA level. Recent clinical studies have shown partial restoration of muscle dystrophin with local and systemic delivery, and international trials are in progress. SMA is the most common severe hereditary disease of infancy. It is characterized by weakness of the extremity and respiratory muscles due to motor neuron loss. SMA is caused by mutations that lead to reduced levels of the survival motor neuron (SMN) protein, which is an important factor in mRNA splicing. Motor neurons may be particularly vulnerable to SMN deficiency because of their unusual structure and function. A variety of cell and animal models are available to test potential SMA treatments. Histone deacetylase inhibitors are beneficial in mice, and this effect can be enhanced by improved nutrition. Clinical trials of drugs that increase SMN have had mixed results to date, and assays to screen for better drugs have been developed. Oligonucleotide and gene replacement therapy have recently shown great promise in animal studies, and clinical trials are planned. Meanwhile, there is evidence that better respiratory and nutritional support can be very helpful. Thus, the clinical outcome may be improved by optimizing currently available treatment. The NIH Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.
Subjects:	Muscular Atrophy, Spinal--drug therapy Muscular Atrophy, Spinal--genetics Muscular Dystrophy, Duchenne--drug therapy Muscular Dystrophy, Duchenne--genetics Oligonucleotides, Antisense--therapeutic use
Publication Types:	Lecture Webcast

NLM Classification:	WE 559
NLM ID:	101574467
CIT Live ID:	10506
Permanent link:	https://videocast.nih.gov/watch=10506

Related Videos...